JP2023545983A5 - - Google Patents
Info
- Publication number
- JP2023545983A5 JP2023545983A5 JP2023520379A JP2023520379A JP2023545983A5 JP 2023545983 A5 JP2023545983 A5 JP 2023545983A5 JP 2023520379 A JP2023520379 A JP 2023520379A JP 2023520379 A JP2023520379 A JP 2023520379A JP 2023545983 A5 JP2023545983 A5 JP 2023545983A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- bispecific antibody
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063088879P | 2020-10-07 | 2020-10-07 | |
| US63/088,879 | 2020-10-07 | ||
| PCT/US2021/071718 WO2022076987A1 (en) | 2020-10-07 | 2021-10-05 | Bispecific antibody treatment of lymphoid malignant neoplasm conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545983A JP2023545983A (ja) | 2023-11-01 |
| JP2023545983A5 true JP2023545983A5 (https=) | 2024-10-10 |
Family
ID=78622127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520379A Pending JP2023545983A (ja) | 2020-10-07 | 2021-10-05 | リンパ系悪性腫瘍状態の二重特異性抗体治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230365681A1 (https=) |
| EP (1) | EP4225793A1 (https=) |
| JP (1) | JP2023545983A (https=) |
| KR (1) | KR20230083300A (https=) |
| CN (1) | CN116685348A (https=) |
| WO (1) | WO2022076987A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025137576A1 (en) * | 2023-12-22 | 2025-06-26 | Nutcracker Therapeutics, Inc. | Multiple specific antibodies targeting cd19, cd20, and/or cd47 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102100388B1 (ko) | 2012-02-06 | 2020-04-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| JP2016514676A (ja) * | 2013-03-15 | 2016-05-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 四価二重特異性抗体 |
| PL3180363T3 (pl) * | 2014-08-15 | 2020-02-28 | Merck Patent Gmbh | Białka fuzyjne immunoglobulin sirp-alfa |
| MX391051B (es) | 2014-12-30 | 2025-03-21 | Celgene Corp | Anticuerpos anti-cd47 y usos de los mismos. |
| CN109689684B (zh) | 2016-07-06 | 2022-09-23 | 细胞基因公司 | 具有低免疫原性的抗体及其用途 |
| WO2018183182A1 (en) | 2017-03-27 | 2018-10-04 | Celgene Corporation | Methods and compositions for reduction of immunogenicity |
| EP3722322A4 (en) * | 2017-12-04 | 2021-09-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | ANTI-PD-L1 / ANTI-CD47 BISPECIFIC ANTIBODY HAVING A NATURAL ANTIBODY STRUCTURE AND IN THE FORM OF A HETERODIMER, AND ASSOCIATED PREPARATION |
| CN111699005A (zh) * | 2018-02-12 | 2020-09-22 | 四十七公司 | 使用抗cd47抗体和抗cd20抗体的抗癌方案 |
-
2021
- 2021-10-05 US US18/248,205 patent/US20230365681A1/en active Pending
- 2021-10-05 WO PCT/US2021/071718 patent/WO2022076987A1/en not_active Ceased
- 2021-10-05 CN CN202180065527.0A patent/CN116685348A/zh active Pending
- 2021-10-05 KR KR1020237014459A patent/KR20230083300A/ko active Pending
- 2021-10-05 EP EP21807476.3A patent/EP4225793A1/en active Pending
- 2021-10-05 JP JP2023520379A patent/JP2023545983A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113347996B (zh) | 治疗肿瘤的联用药物组合物 | |
| RU2679119C2 (ru) | Лечение неопластических заболеваний | |
| CN101365486B (zh) | 使用抗egfr和抗her2抗体的联合治疗 | |
| MD3394103T2 (ro) | Combinație de anticorpi anti-PD-1 și anticorpi bispecifici anti-CD20/anti-CD3 pentru tratamentul cancerului | |
| TW202529804A (zh) | 用於癌症治療的組合療法 | |
| JP2020507577A (ja) | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 | |
| CN119746058A (zh) | 治疗小细胞肺癌的联用药物组合物 | |
| CN118267469A (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
| CN120437288A (zh) | 治疗卵巢癌的药物组合 | |
| JP2023545983A5 (https=) | ||
| US20250090659A1 (en) | Combination therapy with an anti-cd19 antibody and parsaclisib | |
| WO2025122791A1 (en) | Use of anti-cd38 antibody in the treatment of new diagnosed multiple myeloma | |
| CN121622884A (zh) | 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途 | |
| CN119454937A (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| TW202527995A (zh) | 抗b7h3抗體藥物偶聯物在製備治療鼻咽癌和/或肺淋巴上皮瘤樣癌的藥物中的用途 | |
| WO2024230772A1 (zh) | 包含抗her2双特异性抗体的联合治疗药物及其用途 | |
| CN121311504A (zh) | 用针对cd3和cd20的双特异性抗体治疗淋巴瘤的方法 | |
| KR20240149434A (ko) | 암을 치료하기 위한 체크포인트 저해제 및 종양용해 바이러스의 조합 | |
| CN118871128A (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| CN115814076A (zh) | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 | |
| AU2021320130B2 (en) | Treatment of CLL | |
| US20250230242A1 (en) | Pharmaceutical composition of anti-tim-3 antibody and hypomethylating agent | |
| JP2021508699A (ja) | トリプルネガティブ乳がんを処置するためのｐｄ−１抗体及びアパチニブの併用処置の使用 | |
| WO2025140478A1 (zh) | 抗pd-l1/cd47双特异抗体在联合用药中的应用 | |
| WO2025195487A1 (zh) | 靶向Nectin-4的抗体药物缀合物的用途 |